Shares of medical technology firm SI-Bone have surged approximately 55% over the past year, nearly touching their 52-week high of $20.05. This impressive rally, coupled with technical indicators flashing overbought signals, is drawing increased scrutiny from investors. The situation intensified following recent stock sales by a company insider.
Executive Sells Near Price Highs
Anshul Maheshwari, the Chief Financial Officer of SI-Bone, executed sales of company stock on November 21 and November 25. The transactions involved a total of 1,300 shares sold at prices around $20 per share, generating proceeds of roughly $26,015. This move is particularly notable as the stock was trading close to its annual peak, at $19.49, when the sales occurred. Market technicians point to the Relative Strength Index (RSI) suggesting the equity is in overbought territory, a condition that often precedes a price pullback.
The stock’s recent performance has been robust, closing higher in seven of the last ten trading sessions and posting a substantial 24.3% gain over a two-week period.
Financial Performance: Growth Versus Profitability
The company’s latest quarterly report, released in early November, delivered results that surpassed market expectations. However, the core issue of profitability remains unresolved.
Key financial figures from the third quarter include:
* Revenue of $48.7 million, representing a 21% year-over-year increase.
* A loss per share of -$0.11, which was better than the anticipated -$0.17.
* Adjusted EBITDA of $2.3 million, yielding a margin of 5%.
* The company currently holds a market capitalization of $855.24 million.
Should investors sell immediately? Or is it worth buying SI-Bone?
Despite a solid revenue growth trajectory of 23% over the past twelve months, market experts do not project the company will achieve profitability within the current fiscal year.
Conflicting Signals: Bullish Outlook Amid Insider Selling
In a show of confidence, SI-Bone’s management team has raised its full-year guidance. The company now anticipates annual revenue to land between $198 million and $200 million, which would equate to growth of 18% to 20%. Furthermore, management forecasts a gross margin of approximately 79.5% and a positive adjusted EBITDA.
This optimistic view is shared by several Wall Street firms. Cantor Fitzgerald has reaffirmed its “Overweight” rating with a $25 price target, while Needham & Company maintains a “Buy” recommendation with a $24 target.
The convergence of these strong fundamentals and positive analyst sentiment with an insider’s decision to sell at a near-term peak presents a complex picture for investors. The critical question remains whether the company’s underlying growth is substantial enough to support its current valuation in the face of these contrasting signals.
Ad
SI-Bone Stock: Buy or Sell?! New SI-Bone Analysis from February 7 delivers the answer:
The latest SI-Bone figures speak for themselves: Urgent action needed for SI-Bone investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
SI-Bone: Buy or sell? Read more here...
